Drugs / Petrolatum

Trials 5

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03561376 Sep 2021 → Sep 2027 expected — Melissa Pugliano-Mauro Recruiting No outcome recorded
Phase 31 trial · 1 missed
Phase 3 NCT02109718 Jan 2009 → Jul 2010 — University of the Philippines Completed Missed primary
Phase not applicable3 trials
— NCT07531472 May 2026 → Apr 2028 expected — Assiut University Not yet recruiting No outcome recorded
— NCT02338076 Jun 2013 → Feb 2015 skin disorder Rockefeller University Completed No outcome recorded
— NCT01315951 Mar 2011 → Feb 2012 seborrheic dermatitis Ascension Health Terminated No outcome recorded
Comparator or background therapy2 trials
Phase 1 NCT01984775 Comparator Oct 2013 → Jul 2014 psoriasis Stiefel, a GSK Company Completed No outcome recorded
— NCT05553392 Comparator Nov 2022 → May 2024 radiodermatitis Stratpharma AG Terminated No outcome recorded Stop: Enrollment

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as petrolatum “Aquaphor contains 41 percent petrolatum (or petroleum jelly), the active ingredient, temporarily protects minor cuts, scrapes, and burns; protects and helps relieve chapped or...” NCT05553392 ↗
5

“Petrolatum is considered a skin protectant and has a strong ability to hold moisture in skin.” NCT01315951 ↗

“Negative control contains petrolatum.” NCT01984775 ↗

NCT02109718 ↗

NCT02338076 ↗

NCT03561376 ↗

Known as Petroleum jelly ClinicalTrials.gov intervention name — accepted as the source's own label NCT07531472 ↗
Known as Vaseline “The control, standard of care petrolatum (i.e. Vaseline) will be applied to the side indicated by "V"” NCT03561376 ↗
Route Topical “then apply petroleum jelly to the area before bedtime” NCT01315951 ↗